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Several articles have appeared over the last years devoted to mental side effects during zonisamide (ZNS) treatment. In this
study, we were particularly interested in psychotic episodes. Seventy-four epileptic patients with a history of ZNS treatment
were surveyed retrospectively over the period spanning 1 March 1984 to 30 June 1994. They were divided into two groups
according to the presence or absence of psychotic episodes during ZNS treatment. We analysed various factors pertaining to
psychotic episodes during ZNS treatment. Of the 74 patients 14 had psychotic episodes. We found that the incidence of psychotic
episodes during ZNS treatment was several times higher than the previously reported prevalence of epileptic psychosis, and
that the risk of psychotic episodes was higher in young patients. In 13 patients, psychotic episodes occurred within a few
years of commencement of ZNS. In children, obsessive-compulsive symptoms appeared to be related to psychotic episodes.
It is important to terminate ZNS as soon as possible if psychotic episodes develop and never restart, even if seizures become
worse. It cannot definitely be proved that ZNS causes psychotic episodes, as information on mental side effects during ZNS
monotherapy is scant, but it does appear likely that ZNS contributes to psychotic episodes during polytherapy.
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INTRODUCTION
It has been more than 10 years since zonisamide (ZNS)
(1,2-benzisoxazole-3-methanesulfonamide) treatment
was first used in Japan. All drugs have side effects and
ZNS is no exception. A number of articles have ap-
peared over the last few years devoted to the clinical
study of psychosis during ZNS treatment1–4. In this
study, we focused on psychotic episodes during ZNS
treatment and analysed various related factors.
Zonisamide is an antiepileptic drug (AED) with
a basic skeleton of benzisoxazole, and a similar
antiepileptic profile to those of carbamazepine (CBZ)
and phenytoin (PHT)5. The antiepileptic action of
ZNS is to suppress epileptogenic focus and subse-
quent seizure propagation6. It is also effective psy-
chopharmacologically in treating affective disorders
(i.e. manic state in bipolar disorder)7. Yagi and Seino8,
however, reported a number of acute side effects with
ZNS: drowsiness, ataxia, loss of appetite, decreased
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spontaneity, slowing of mental activity and skin le-
sions. Berent et al.9 reported that ZNS affected cog-
nitive functions, although Kubota et al.10 reported that
ZNS did not affect the event-related potential: p300.
In addition, several articles have noted certain mental
side effects with ZNS: depression, psychotic episode
and behaviour disorder4, 11. However, it should be
noted that these mental side effects have usually ap-
peared during polytherapy with AEDs, rarely during
monotherapy with ZNS4. It remains unclear, there-
fore, as to whether these mental side effects during
polytherapy were actually due to ZNS, because of the
prevalence of epileptic psychosis, as previously re-
ported, 2.4–4.4%12 and the fact that other AEDs also
engender mental side effects13. Questions, then, arise
as to the incidence of and factors related to ZNS-
induced mental side effects. Here, we were partic-
ularly concerned with psychotic episodes, being the
severest and those which most seriously affect the
quality of life. The two most prominent cases are pre-
sented in detail.
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MATERIALS AND METHODS
Seventy-four epileptic patients with a history of ZNS
treatment were surveyed retrospectively over the pe-
riod spanning 1 March 1984 to 30 June 1994. In this
study, we defined psychotic episode as being in a state
of delusion and/or hallucination. Therefore, patients
with psychotic episodes met the ICD-10 criteria for or-
ganic delusional (schizophrenia-like) disorder and or-
ganic hallucinosis. In other words, psychotic episode
here does not include organic mood (affective) disor-
ders. Patients were divided into two groups accord-
ing to the presence or absence of psychotic episodes
during ZNS treatment: a psychotic group and a con-
trol group, respectively. We analysed the following
factors: gender, age, age at onset of epilepsy, period
of epilepsy, frequency of seizures, classification of
epilepsy, period of AEDs treatment, period of ZNS
treatment, histories of PHT and/or CBZ, lesions in
imaging studies, neurotic symptoms, personality dis-
orders and mental retardation. We focused on PHT
and CBZ as our AEDs as they are the two most com-
monly used in combination with ZNS. Gender, fre-
quency of seizures, classification of epilepsy, and his-
tory of PHT were analysed using a χ2-test. History of
CBZ, presence of lesions in imaging studies, neurotic
symptoms, personality disorders and mental retarda-
tion in the two groups were analysed using Fisher’s
exact probability test. Classification of epilepsy was
diagnosed with history, interictal and ictal EEG ac-
cording to ILEA classification. Frequency of seizures
consisted of two categories: (1) frequent seizures oc-
curring daily, weekly, or monthly, and (2) rare seizures
occurring yearly or seizure free. Classification of
epilepsy consisted of three categories: (1) temporal
lobe epilepsy (TLE); (2) partial epilepsy (non-TLE);
(3) generalized epilepsy. ‘History of PHT treatment or
CBZ treatment’ was defined as the presence of either
treatment during ZNS treatment in the control group,
and as the presence of either treatment at the onset of
psychotic episode in the psychotic group. One patient
from the control group and one patient from the psy-
chotic group were absent from the imaging study, and
were, therefore, excluded from the analysis thereof.
Neurotic symptoms consisted of anxiety symptoms,
obsessive-compulsive symptoms, dissociative symp-
toms and somatoform symptoms; patients with neu-
rotic symptoms met the ICD-10 criteria for organic
anxiety disorder, organic dissociative disorder, organic
emotionally labile disorder, and other specified men-
tal disorders due to brain damage and dysfunction
and to physical disease. Patients with personality dis-
orders met the ICD-10 criteria for organic personal-
ity disorder. Age, age at onset of seizure, period of
epilepsy and period of AEDs treatment in each group
were analysed statistically using an unpaired Student’s
t-test. Period of ZNS treatment was analysed using
the Mann–Whitney test. ‘Age’ was defined as age on
30 June 1994 in the control group, and as age at the
onset of psychotic episode in the psychotic group. ‘Pe-
riod of AEDs treatment and ZNS treatment’ was de-
fined as the period from the beginning of each treat-
ment to 30 June 1994 in the control group, and as the
period from the beginning of each treatment to the on-
set of psychotic episodes in the psychotic group.
PROMINENT CASES
Case 14
A 45-year-old male patient with frontal-lobe
epilepsy (FLE); paralysis of the left upper and lower
extremities had developed at the age of 44. A CT scan
demonstrated a brain tumour in the right frontal lobe,
which was then totally removed on 2 September 1991
in the department of neurosurgery at Hokkaido Uni-
versity Hospital. The tumour was histologically di-
agnosed as glioblastoma, and irradiation therapy and
chemotherapy were carried out. The first seizure oc-
curred just after the operation and was described as
a motor seizure in the left upper extremity. Ther-
apy with AEDs was then started (ZNS at a dosage of
200 mg day−1 and PHT at a dosage of 300 mg day−1).
He left the hospital 1 month after the operation, and
his mental state showed no change when compared
with that of his presurgery state. Insomnia, loss of ap-
petite, hypobulia, and loss of interest developed after
the dosage of ZNS was increased to 300 mg day−1
following a second motor seizure on 18 December. A
psychotic episode consisting of visual hallucination
and delusion of reference appeared in the last week of
January 1992. He was then admitted to the department
of psychiatry and neurology on 30 January. ZNS was
decreased promptly, later to be discontinued, and an-
tipsychotic drugs introduced. His psychotic episodes
then ceased immediately, never to reappear after the
withdrawal of antipsychotic drugs.
Case 2
A girl with FLE; birth and psychomotor development
were initially normal. Complex partial seizures (CPSs)
began in May 1986 when she was 6 years old, 3 days
after the onset of scarlet fever. These seizures con-
sisted of a frightened expression and motor automa-
tisms (e.g. climbing, jumping and screaming). Ther-
apy with AEDs was commenced using sodium val-
proate and CBZ, 10 days after the onset of epilepsy.
She visited our epilepsy clinic in October 1986.
Because she later developed CPSs and secondary
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generalized seizures daily, ZNS was added to PHT
monotherapy in May 1991 when she was 12 years
old. Although ZNS proved effective, tic, a psychotic
episode with auditory hallucinations and delusions of
persecution and reference, and obsessional thoughts
appeared 2 months after its introduction. It was im-
mediately withdrawn and the psychotic symptoms dis-
appeared. Therapy with ZNS was tried again several
times in an attempt to control refractory seizures, al-
though each time these psychotic symptoms would
reappear, only to disappear again when treatment was
withdrawn. Primidone was added in March 1992. Be-
cause her psychotic episode became irreversible in
May, when she was 13 years old, she was admitted to
the department of psychiatry and neurology. Although
ZNS was discontinued, the psychotic episodes showed
only a slight improvement. Ictal EEG during admis-
sion demonstrated spikes in the left frontal area and
delta activity spreading from the left frontal area to all
the other areas. CPSs consisted of staring, screaming,
tonic arrest and autonomic symptoms (e.g. mydriasis,
pilo-erection of skin, incontinence of urine), and had a
tendency to be nocturnal and occur in clusters. These
findings indicated a left medial frontal lobe origin.
RESULTS
Fourteen (18.9%) of the 74 patients exhibited psy-
chotic episodes during ZNS treatment. Table 1 shows
the clinical profiles and factors of the psychotic
group. Table 2 shows the numbers for each factor
in both groups. There were significantly more male
patients than female patients in the psychotic group
(P < 0.05). Patients with psychotic episodes were
significantly younger than those without (P < 0.01).
Differences in age at onset of epilepsy, classifica-
tion of epilepsy and frequency of seizure between the
two groups were not significant. Period of epilepsy
(P < 0.01), AEDs treatment (P < 0.01) and ZNS
treatment (P < 0.01) were significantly shorter in the
psychotic group than in the controls. Histories of PHT
and CBZ were not significant. The presence of lesions
in imaging studies was not significant. The presence
of neurotic symptoms was significantly higher in the
psychotic group than in the control group (P < 0.05).
Presence of personality disorders and mental retarda-
tion showed no significant differences.
DISCUSSION
Using ICD-10 criteria for retrospective diagnosis is
rather unreliable. However, we did so in order to be
clear what patients with psychotic episodes meant in
this study. We consulted a number of clinical records
compiled by various qualified psychiatrists, almost
half of which were written by ourselves, in order to
make this ICD-10 diagnosis.
In this study, we investigated only psychotic
episodes. Several cases of depression during ZNS
treatment have been reported4. It has been shown that
ZNS is effective in treating affective disorders psy-
chopharmacologically (i.e. manic state in bipolar dis-
order)7.
Case 14 was an FLE patient who had had a brain
tumour removed, and in whom there was a clear cor-
relation between psychotic episodes and ZNS treat-
ment, with psychotic episodes occurring just after an
increase of ZNS dosage and disappearing immedi-
ately after its withdrawal. The course of the psychotic
episodes here suggests that they were induced by ZNS.
Case 2 was a girl with FLE. Here, each repetition
of ZNS treatment caused psychotic episodes to recur.
Initially, her psychotic episodes had been reversible.
However, their becoming irreversible was probably
caused by repeated application of ZNS treatment. Let
us stress, then, that ZNS treatment must be perma-
nently discontinued if psychotic episodes occur.
In 10 out of the 14 patients with psychotic episodes,
antipsychotic medication was effective and they made
a good recovery. In three (cases 1, 2 and 3) of the four
remaining cases, psychotic episodes had occurred dur-
ing their teens (12, 12, and 17 years old, respectively).
One multi-institutional study reported that the in-
cidence of psychotic episodes during ZNS treatment
over a period of 38 months was 1.1%14. However,
in this study, that for a period of 124 months was
found to be 18.9% (14 of 74). One reason for the
higher incidence in our study is that five of the pa-
tients had consulted our clinic specifically for treat-
ment for psychotic episodes. Even if they were ex-
cluded though, the corrected incidence would still be
higher at 13.0% (9 of 69) than that in the previous
study. Its incidence was also several times higher than
the previously reported prevalence of epileptic psy-
chosis (i.e. 2.4–4.4%)12 and higher than that of epilep-
tic psychosis in TLE (i.e. 10.3%)15.
In this study, there were more males than females in
the psychotic group. However, gender distribution of
schizophrenia-like psychosis in epilepsies appears to
be almost even from previous studies12. Gender dif-
ferences in the incidence of psychotic episodes dur-
ing ZNS treatment have not been reported. We have
only limited information on sex distribution and there
is room here for further investigation.
Several articles have reported a correlation between
age at onset of epilepsy and psychotic symptoms16, 17.
However, age at onset of epilepsy showed no sig-
nificant difference between the two groups in this
study, agreeing with other reports that found no signif-
icant difference between psychotic and non-psychotic
epileptic populations12.
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Table 1: Clinical profile and factors of psychotic group.
No. Gender Age Age at onset Period of Frequency Classification Period Period Dose History History Lesions Neurotic Personality Mental
(years) of epilepsy epilepsy of of of of of of of in symptoms changes retardation
(years) (years) seizurea epilepsyb AED (years) ZNS (months) ZNS (mg) PHT CBZ imaging
1 F 12 5 6 Y PE 5 0 100 − + − + − −
2 F 12 7 4 D FLE 4 2 50 + + − + − +
3 M 17 7 10 M PE 10 2 300 + − —c − − +
4 M 23 1 22 D TLE 22 3 600 + + + − + +
5 M 25 8 17 D TLE 17 122 400 + + − − + −
6 M 21 9 12 W TLE 12 1 150 − + − + + −
7 M 26 8 18 W PE 18 20 400 − + − + + −
8 M 25 11 14 H TLE 14 13 500 − − − − − −
9 M 26 15 11 M LGS 11 42 300 + + + − − +
10 M 27 9 18 Y TLE 18 29 400 + + − + − −
11 M 26 16 10 M TLE 10 15 400 − + + − + +
12 M 33 19 14 W TLE 14 79 400 + + + + + −
13 M 42 17 25 W TLE 4 8 200 + + − − + −
14 M 45 44 1 Y FLE 1 4 300 + − + − − −
a Y, yearly; M, monthly; W, weekly; D, daily. b TLE, temporal lobe epilepsy; FLE, frontal lobe epilepsy; PE, partial epilepsy (non-TLE); LGS, Lennox–Gastaut syndrome. c Imaging study was not available.
Table 2: Numbers of factors in each patient group.




Age (years) 36.48 (12.6) 25.71 (9.5) ∗∗
Age at onset of seizures (years) 13.85 (10.4) 12.57 (10.3) NS
Period of epilepsy (years) 22.52 (11.7) 13.00 (6.7) ∗∗
Frequency of seizures frequenta 36 11 NS
rare 24 3
Classification of epilepsy TLEb 34 8 NS
PE (non-TLE) 20 5
GE 6 1
Period of AED treatment (years) 21.63 (11.3) 11.4 (6.2) ∗∗
Period of ZNS treatment (months) 42.37 (32.5) 24.28 (35.5) ∗∗
History of PHT NS
+ 27 10
− 33 4
History of CBZ NS
+ 46 11
− 14 3











∗P < .05, ∗ ∗ P < .01, NS: not significant. Standard deviations are given in parentheses. a Frequent, daily, weekly and monthly; rare, yearly or seizure free, b TLE, temporal lobe epilepsy; PE, partial epilepsy; GE,
generalized epilepsy.
Period of epilepsy in the psychotic group was
13 years, shorter than that in previous studies (i.e.
15–22 years), and the onset of psychotic episode was
27.9 years old, younger than that in previous stud-
ies (i.e. 30–34 years old)12. These results suggest that
ZNS shortened the time to the onset of psychotic
episode, or possibly even caused psychotic episodes.
The psychotic group was younger than the control
group. This suggests that care should be taken in in-
troducing ZNS in younger patients, particularly chil-
dren. Indeed, ZNS appears to have contributed to psy-
chotic episodes in two children (cases 1 and 2). In ad-
dition, psychotic episodes in these cases proved refrac-
tory to antipsychotic drugs. Kimura also reported that
ZNS caused behaviour disorders in two children11. It
is obvious, therefore, that ZNS can induce mental side
effects in children.
In half of the psychotic patients, psychotic episodes
occurred within 1 year. Four patients developed them
within a period of 1–3 years; 11 out of the 14 patients
showed them within 3 years. This suggests that pa-
tients should be carefully monitored for a 3-year pe-
riod following on from the commencement of treat-
ment with ZNS.
There is no significant difference in frequency
of seizure between the two groups. No paradoxical
normalization was observed in the psychotic group.
Case 5 showed psychosis after a cluster of CPS.
The others showed no correlation between psychotic
episodes and seizures.
The past few decades have seen a number of re-
ports on the relation between psychosis and TLE, es-
pecially left focus16, 17, and a number of TLE patients
exhibiting psychotic episodes during ZNS treatment
have been reported1–4. Some studies1, 4 have reported
that the incidence of psychosis during ZNS treatment
was higher in TLEs than in non-TLE partial epilepsies.
However, the incidence of psychotic episodes was not
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found to be higher in the TLEs in this study. Let us
stress that psychotic episodes can occur in any type of
epilepsy during ZNS treatment. A number of cases of
generalized epilepsies have been reported4, 18.
Psychotic episodes during ZNS monotherapy have
rarely been reported4. All the cases with psychotic
episodes in this study were under polytherapy. Al-
though several articles have reported a relation be-
tween psychosis and the combination of ZNS and
PHT, no significant difference was shown here be-
tween PHT and CBZ in combination with ZNS.
The assumption that disturbances in the cerebral
mono-amine metabolism may underlie epileptic psy-
chosis is widely accepted19. From this point of view, it
would not be appropriate to assert that a combination
of ZNS with CBZ is safer than that with PHT, as both
ZNS and CBZ increase the extracellular and intraneu-
ronal levels of dopamin in the striatum and hippocam-
pus in rat at a therapeutic dosage20, whereas PHT does
not21.
There were more patients with neurotic symptoms
in the psychotic group than in the control group. The
important point to note here is that two of the chil-
dren showed obsessive-compulsive symptoms just be-
fore (case 1), or almost concurrently (case 2), with
the onset of psychotic episodes. This suggests that
such obsessive-compulsive symptoms may be related
to psychotic episode. Therefore, especially in the case
of children, it is important to terminate ZNS treatment
immediately should such obsessive-compulsive symp-
toms occur.
Slater and Beard reported that 51 out of 69 cases of
schizophrenia-like psychosis in epilepsy showed signs
of personality disorders. However, only two patients
were recorded as schizoid and nine as paranoid. They
concluded, therefore, that premorbid personality was
not related to psychosis16. Our result, that the presence
of personality disorders did not show a significant dif-
ference between the two patient groups, concurs with
their view.
In the research of Jensen and Larsen22, psychotic
epilepsy patients were of higher intelligence and
achievement than non-psychotic epilepsy patients. We
found no difference between our two patient groups
as regards the presence of mental retardation. Mental
retardation, therefore, probably does not contribute to
psychotic episodes during ZNS treatment.
To summarize, this study revealed that the incidence
of psychotic episodes during ZNS treatment was sev-
eral times higher than the previously reported preva-
lence of epileptic psychosis, and that the risk of psy-
chotic episodes was higher in young patients. In 13 out
of the 14 patients, psychotic episodes occurred within
a few years of starting ZNS. In children, obsessive-
compulsive symptoms appear to be related to psy-
chotic episodes during ZNS treatment. It is impor-
tant to permanently withdraw ZNS as soon as possi-
ble should psychotic episodes develop, even if seizures
worsen. It cannot definitely be proved that ZNS causes
psychotic episodes as information on mental side ef-
fects during ZNS monotherapy is scant. However, it
seems likely that ZNS contributes to psychotic episode
during polytherapy.
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